摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(氨基羰基)氨基]-5-溴噻吩-3-羧酸甲酯 | 845889-21-6

中文名称
2-[(氨基羰基)氨基]-5-溴噻吩-3-羧酸甲酯
中文别名
——
英文名称
methyl 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxylate
英文别名
Methyl 5-bromo-2-ureidothiophene-3-carboxylate;methyl 5-bromo-2-(carbamoylamino)thiophene-3-carboxylate
2-[(氨基羰基)氨基]-5-溴噻吩-3-羧酸甲酯化学式
CAS
845889-21-6
化学式
C7H7BrN2O3S
mdl
——
分子量
279.114
InChiKey
NOCKNFYBIYMQPG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    364.8±42.0 °C(Predicted)
  • 密度:
    1.821±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    110
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[(氨基羰基)氨基]-5-溴噻吩-3-羧酸甲酯盐酸四(三苯基膦)钯三甲基铝caesium carbonate 作用下, 以 四氢呋喃1,4-二氧六环甲醇 为溶剂, 反应 1.0h, 生成 5-(3-chlorophenyl)-2-ureidothiophene-3-carboxylic acid (S)-piperidin-3-ylamide hydrochloride
    参考文献:
    名称:
    Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas
    摘要:
    Checkpoint kinases CHK1 and CHK2 are activated in response to DNA damage that results in cell cycle arrest, allowing sufficient time for DNA repair. Agents that lead to abrogation of such checkpoints have potential to increase the efficacy of such compounds as chemo- and radiotherapies. Thiophenecarboxamide ureas (TCUs) were identified as inhibitors of CHK1 by high throughput screening. A structure-based approach is described using crystal structures of JNK1 and CHK1 in complex with 1 and 2 and of the CHK1-3b complex. The ribose binding pocket of CHK1 was targeted to generate inhibitors with excellent cellular potency and selectivity over CDK1 and IKK beta, key features lacking from the initial compounds, Optimization of 3b resulted in the identification of a regioisomeric 3-TCU lead 12a. Optimization of 12a led to the discovery of the clinical candidate 4 (AZD7762), which strongly potentiates the efficacy of a variety of DNA-damaging agents in preclinical models.
    DOI:
    10.1021/jm300025r
  • 作为产物:
    描述:
    methyl 2-({[(trichloroacetyl)amino]carbonyl}amino)thiophene-3-carboxylate 在 溶剂黄146 作用下, 以 甲醇 为溶剂, 生成 2-[(氨基羰基)氨基]-5-溴噻吩-3-羧酸甲酯
    参考文献:
    名称:
    Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas
    摘要:
    Checkpoint kinases CHK1 and CHK2 are activated in response to DNA damage that results in cell cycle arrest, allowing sufficient time for DNA repair. Agents that lead to abrogation of such checkpoints have potential to increase the efficacy of such compounds as chemo- and radiotherapies. Thiophenecarboxamide ureas (TCUs) were identified as inhibitors of CHK1 by high throughput screening. A structure-based approach is described using crystal structures of JNK1 and CHK1 in complex with 1 and 2 and of the CHK1-3b complex. The ribose binding pocket of CHK1 was targeted to generate inhibitors with excellent cellular potency and selectivity over CDK1 and IKK beta, key features lacking from the initial compounds, Optimization of 3b resulted in the identification of a regioisomeric 3-TCU lead 12a. Optimization of 12a led to the discovery of the clinical candidate 4 (AZD7762), which strongly potentiates the efficacy of a variety of DNA-damaging agents in preclinical models.
    DOI:
    10.1021/jm300025r
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED THIOPHENES AND USES THEREOF<br/>[FR] THIOPHENES SUBSTITUES ET LEURS UTILISATIONS
    申请人:ASTRAZENECA AB
    公开号:WO2005016909A1
    公开(公告)日:2005-02-24
    This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    这项发明涉及具有结构式(I)的新化合物,以及它们的药用盐、组合物和使用方法。这些新化合物可用于治疗或预防癌症。
  • Thiophene derivatives as chk 1 inhibitors
    申请人:Ashwell Susan
    公开号:US20070010556A1
    公开(公告)日:2007-01-11
    This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    本发明涉及具有结构式(I)的新化合物,以及它们的制药组合物和使用方法。这些新化合物提供了治疗或预防癌症的方法。
  • Substitute thiophenes and uses therof
    申请人:Ashwell Susan
    公开号:US20060281666A1
    公开(公告)日:2006-12-14
    This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    本发明涉及具有结构式(I)的新化合物及其药物盐、组合物和使用方法。这些新化合物提供了治疗或预防癌症的方法。
  • SUBSTITUTED THIOPHENES AND USES THEREOF
    申请人:Ashwell Susan
    公开号:US20090054396A1
    公开(公告)日:2009-02-26
    This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    本发明涉及具有结构式(I)的新化合物及其药物盐、组合物和使用方法。这些新化合物提供了癌症的治疗或预防。
  • Thiophene and thiazole derivatives as CHK1 inhibitors
    申请人:AstraZeneca AB
    公开号:EP2305671A1
    公开(公告)日:2011-04-06
    This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    本发明涉及具有结构式 (I) 的新型化合物 及其药物组合物和使用方法。这些新型化合物可治疗或预防癌症。
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯